The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|June 20, 2013
Rexam Healthcare Expands Manufacturing for Drug Delivery Systems
Author(s)Pharmaceutical Technology Editors
New production capabilities in Normandy, France will include a cleanroom.
Advertisement
Rexam Healthcare, a subsidiary of the UK group Rexam, will expand manufacturing capabilities at its French site in Le Tréport, Seine Maritime, the company announced in a
This site specializes in drug delivery systems, including the recently introduced Advancia pump for the nasal-spray sector. The plant expansion and the Advancia project, which is supported by the European Regional Development Fund in Normandy, will add approximately fifty jobs.
Along with other site improvements, the manufacturing expansion will include a production building with a 2900-square meter cleanroom and 1500 square meters housing the machine and mold maintenance workshops, metrology unit, laboratory, and administrative premises. The cleanroom is expected to open in November 2013 and full inauguration of the site is expected in early 2014.
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
Advertisement
Advertisement